Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1906 in Idiopathic Pulmonary Fibrosis
NCT05722964Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1906 in idiopathic pulmonary fibrosis (IPF), sponsored by Hengrui Therapeutics. Started Mar 2023; status: completed.
02
Drugs
SHR-1906
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05722964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722964.